Entera To Present EB613, Once Daily PTH(1-34) Tablet Treatment Dedicated To Post-Menopausal Women With High Risk Osteoporosis Abstract At The ASBMR 2024 Annual Meeting; Key SABRE Update Also Expected
Portfolio Pulse from Benzinga Newsdesk
Entera Bio Ltd. (NASDAQ:ENTX) will present new data on its investigational agent EB613, a once-daily oral PTH(1-34) mini tablet therapy for post-menopausal women with high-risk osteoporosis, at the ASBMR 2024 Annual Meeting. The presentation will include comparative pharmacological data between EB613 and Forteo®.
August 01, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Entera Bio Ltd. (NASDAQ:ENTX) will present new comparative pharmacological data for its investigational agent EB613 at the ASBMR 2024 Annual Meeting. This could potentially boost investor confidence in the company's innovative osteoporosis treatment.
The presentation of new data at a major conference like ASBMR can increase visibility and credibility for Entera Bio's EB613. Positive comparative data against an established treatment like Forteo® could lead to increased investor confidence and a potential short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100